ライフサイエンスコーパス: PAPP-A

1 PAPP-A >6.0 muIU/ml at presentation was associated with

2 PAPP-A also improved the net reclassification for CVD/MI

3 PAPP-A is a high molecular weight, zinc-binding metallop

4 PAPP-A is a new candidate marker of unstable angina and

5 PAPP-A is present in unstable plaques, and circulating l

6 PAPP-A levels correlated with levels of C-reactive prote

7 PAPP-A mRNA was expressed by the human fibroblasts and o

8 PAPP-A was abundantly expressed in plaque cells and extr

9 PAPP-A was also associated with higher rates of CVD (HR:

10 PAPP-A was independently associated with recurrent cardi

11 PAPP-A, PCSK9, and ST2 have been regarded as promising c

12 PAPP-A, proMBP, and C-reactive protein (hs-CRP) serum le

13 ease (P<0.001), aspirin treatment (P<0.001), PAPP-A levels (P<0.001), and PAPP-A/proMBP ratio (P<0.00

14 Our results demonstrate that 1) PAPP-A increases the proliferation and differentiation o

15 governed by its proteolytic activity, and 3) PAPP-A promotes skeletal myogenesis by increasing the am

16 A PAPP-A threshold value of 10 mlU per liter identified pa

17 ls of pregnancy-associated plasma protein A (PAPP-A) in the lowest fifth percentile compared with 17

18 uated pregnancy-associated plasma protein A (PAPP-A), a potentially proatherosclerotic metalloprotein

19 inase pregnancy-associated plasma protein-A (PAPP-A) has been implicated in coronary plaque disruptio

20 Pregnancy-associated plasma protein-A (PAPP-A) is a large metalloproteinase specifically cleavi

21 ether pregnancy-associated plasma protein-A (PAPP-A) is useful for risk assessment in non-ST-segment

22 Pregnancy-associated plasma protein-A (PAPP-A), a member of the metalloproteinase superfamily,

23 Pregnancy-associated plasma protein-A (PAPP-A), a metalloproteinase in the insulin-like growth

24 ng as pregnancy-associated plasma protein-A (PAPP-A), a protein of unknown function found in high con

25 nase, pregnancy-associated plasma protein-A (PAPP-A), which modulates insulin-like growth factor (IGF

26 nase, pregnancy-associated plasma protein-A (PAPP-A).

27 ency, pregnancy-associated plasma protein A [PAPP-A], and the free beta subunit of human chorionic go

28 Antibodies raised against PAPP-A both inhibited and immunodepleted IGFBP-4 proteas

29 ment (P<0.001), PAPP-A levels (P<0.001), and PAPP-A/proMBP ratio (P<0.001) were correlated with the n

30 atio (3.1+/-1.2 versus 2.7+/-0.8x10(-3)) and PAPP-A levels (5.9+/-1.6 versus 5.1+/-1.4 mIU/L) than th

31 In patients with stable angina, PAPP-A and PAPP-A/proMBP ratio are associated with angiographic pla

32 er, age, severe coronary artery disease, and PAPP-A/proMBP ratio were independent predictors of the n

33 y the human fibroblasts and osteoblasts, and PAPP-A protein was secreted into the culture medium.

34 sought to assess whether PAPP-A, proMBP, and PAPP-A/ProMBP ratio are markers of angiographic plaque c

35 WT/WT and PAPP-A KO mice showed little or no lesion development ev

36 nd were 10-fold higher than in the WT/WT and PAPP-A KO mice.

37 In patients with stable angina, PAPP-A and PAPP-A/proMBP ratio are associated with angio

38 ased assay that STC1 effectively antagonizes PAPP-A-mediated type 1 IGF receptor (IGF1R) phosphorylat

39 (KO), PAPP-A KO, wild-type (WT/WT), and ApoE/PAPP-A double KO (KO/KO) mice.

40 Circulating PAPP-A levels were significantly higher in patients with

41 , hypertension, and coronary artery disease, PAPP-A was independently associated with CVD/myocardial

42 Addition of exogenous PAPP-A also increased the myotube formation and the acti

43 tenoses had a significantly (P<0.001) higher PAPP-A/proMBP ratio (3.1+/-1.2 versus 2.7+/-0.8x10(-3))

44 ly conserved zebrafish homologs of the human PAPP-A gene.

45 poE KO aortas had 8- to 20-fold increases in PAPP-A, IGFBP-4, and IGF-I mRNA levels compared with non

46 TC2, STC2(C120A), which is unable to inhibit PAPP-A, grow like wild-type mice.

47 ntly, we show that STC2 efficiently inhibits PAPP-A-mediated IGF receptor signaling in vitro and that

48 STC1 potently (Ki = 68 pm) inhibits PAPP-A cleavage of IGFBP-4, and we show in a cell-based

49 been found that the homologous STC2 inhibits PAPP-A proteolytic activity, and that this depends on th

50 icient mice, generating ApoE knock-out (KO), PAPP-A KO, wild-type (WT/WT), and ApoE/PAPP-A double KO

51 Transient overexpression of the full-length PAPP-A-(1-1547), but not truncated protease-inactive N-t

52 We measured PAPP-A at baseline in 3,782 patients with non NSTE-ACS r

53 Moreover, PAPP-A purified from pregnancy sera had IGF-dependent IG

54 n of myoblasts, 2) the stimulatory effect of PAPP-A on myogenesis is governed by its proteolytic acti

55 We examined the level of expression of PAPP-A in eight culprit unstable coronary plaques and fo

56 t evidence for a non-proteolytic function of PAPP-A.

57 llele) compromised proteolytic inhibition of PAPP-A and increased cleavage of IGFBP-4 in vitro, resul

58 o relationship between having a low level of PAPP-A and maternal age, ethnicity, parity, height, body

59 nalyzed by cause of stillbirth, low level of PAPP-A was strongly associated with stillbirth due to pl

60 We also measured circulating levels of PAPP-A, C-reactive protein, and insulin-like growth fact

61 Overexpression of PAPP-A led to degradation of the IGFBP-2 produced by C2C

62 However, the role of PAPP-A and its mechanism of action in various cellular p

63 this study, we have investigated the role of PAPP-A in skeletal myogenesis using C2C12 myoblasts.

64 tioned medium of HT1080 cells overexpressing PAPP-A.

65 Binding of STC2 prevents PAPP-A cleavage of insulin-like growth factor-binding pr

66 Recombinant PAPP-A was purified from the conditioned medium of HT108

67 AMA was associated with lower maternal serum PAPP-A and sFlt and a higher PlGF:sFlt ratio.

68 ith clinical indicators plus BNP, cTnI, ST2, PAPP-A, and MPO (each p</=0.01) [corrected].

69 This finding supports PAPP-A as a candidate prognostic marker in patients with

70 tive N-terminal PAPP-A-(1-920) or C-terminal PAPP-A-(1100-1547), significantly enhanced the prolifera

71 t not truncated protease-inactive N-terminal PAPP-A-(1-920) or C-terminal PAPP-A-(1100-1547), signifi

72 ro and in situ experiments demonstrated that PAPP-A cleaves insulin-like growth factor-binding protei

73 These data indicate that PAPP-A plays a critical role in lesion development in a

74 e-resistant IGFBP-4 completely abolished the PAPP-A-induced proliferation of C2C12 myoblasts.

75 It rather binds to PAPP-A with high affinity (KD = 75 pm).

76 nd that STC1 is unable to bind covalently to PAPP-A, in agreement with the absence of a corresponding

77 and at the same time assigned a function to PAPP-A.

78 ibition requires covalent binding of STC2 to PAPP-A and is mediated by a disulfide bond, which involv

79 We sought to assess whether PAPP-A, proMBP, and PAPP-A/ProMBP ratio are markers of a

80 To determine whether PAPP-A plays an active role in the development of athero

81 ed mice lacking apolipoprotein E (ApoE) with PAPP-A-deficient mice, generating ApoE knock-out (KO), P

82 as no difference in the risk associated with PAPP-A stratified by baseline cardiac troponin I [Accu-T

83 Treatment of C2C12 myoblasts with PAPP-A increased their proliferation in a dose- and time